By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Enanta Pharmaceuticals, Inc. 

500 Arsenal Street

Watertown  Massachusetts  02472  U.S.A.
Phone: 617-607-0800 Fax: 617-607-0530


SEARCH JOBS


Industry
Pharmaceutical






Company News
Enanta Pharmaceuticals, Inc. To Host Conference Call On August 7 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Third Quarter Ended June 30, 2017 7/26/2017 7:37:45 AM
Enanta Pharmaceuticals, Inc. Announces New Data On EDP-938, A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV), At The XIX International Symposium On Respiratory Viral Infections 6/26/2017 5:56:26 AM
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV) Receives CHMP Positive Opinion For MAVIRET (Glecaprevir/Pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6) 6/23/2017 6:29:41 AM
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2017 5/9/2017 6:46:58 AM
Enanta Pharmaceuticals, Inc. Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) 4/20/2017 6:06:50 AM
Enanta Pharmaceuticals, Inc. To Host Conference Call On May 8 At 4:30 P.M. ET To Discuss Financial Results For Its Fiscal Second Quarter Ended March 31, 2017 4/19/2017 6:57:22 AM
Enanta Pharmaceuticals, Inc. Announces New Preclinical Data On Its FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) And Primary Biliary Cholangitis (PBC) At The International Liver Congress 2017 4/19/2017 6:26:37 AM
Enanta Pharmaceuticals, Inc. Announces Japanese Ministry Of Health, Labour And Welfare Grants Priority Review For AbbVie (ABBV)’s Investigational HCV Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of All Major Genotypes Of Chronic Hepatitis C 3/14/2017 7:41:46 AM
Enanta Pharmaceuticals, Inc. Announces CHMP Grants Positive Opinion For An Eight-Week Treatment Option With AbbVie (ABBV)’s VIEKIRAX(Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) For Patients With Genotype 1b Chronic Hepatitis C 2/27/2017 7:02:03 AM
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2016 2/9/2017 6:31:52 AM
12345678910...
//-->